तुलना करने के लिए मीट्रिक्स | GYRE | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंधGYREपीअर्सक्षेत्र | |
|---|---|---|---|---|
पी/ई अनुपात | −101.1x | −9.6x | −0.3x | |
PEG अनुपात | 0.22 | −0.09 | 0.00 | |
क़ीमत/बुक | 6.3x | 5.9x | 2.6x | |
क़ीमत / एलटीएम बिक्री | 5.5x | 13.8x | 3.0x | |
अपसाइड (विश्लेषक लक्ष्य) | 209.8% | 51.5% | 56.6% | |
उचित मूल्य अपसाइड | अनलॉक करें | 3.2% | 10.2% | अनलॉक करें |
Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis. It is also involved in the development of F351 (Hydronidone), a structural derivative of ETUARY, under Phase 3 trials for the treatment of chronic hepatitis B (CHB)-associated liver fibrosis; and completed Phase 1 trials for the treatment of liver fibrosis associated with metabolic dysfunction-associated steatohepatitis. In addition, the company develops F573 is in Phase 2 clinical trials for the treatment of acute/acute-on-chronic liver failure. Further, its preclinical products include F230 for the treatment of pulmonary arterial hypertension; and F528 to treat chronic obstructive pulmonary disease. Gyre Therapeutics, Inc. was founded in 2002 and is headquartered in San Diego, California. Gyre Therapeutics, Inc. operates as a subsidiary of GNI USA, Inc.